

## ENFORTUMAB VEDOTIN

An investigational antibody–drug conjugate directed to Nectin-4

### Anti-Nectin-4 antibody

Fully human monoclonal antibody that binds to Nectin-4

### MMAE

Microtubule-disrupting agent

### Protease-cleavable mc-vc linker

Covalently attaches MMAE to the antibody and releases agent within the target cell

### Nectin-4


- Highly expressed in urothelial carcinoma and certain other solid malignancies, with low-to-moderate expression in normal tissue<sup>1,2</sup>
- High expression of Nectin-4 is associated with poor prognosis in select solid malignancies<sup>3</sup>

**mc-vc**: maleimidocaproyl-valine-citrulline; **MMAE**: monomethyl auristatin E

1. Challita-Eid PM, et al. *Cancer Res.* 2016;76(10):3003-3013. 2. Boylan KLM, et al. *Oncotarget.* 2017;8(6):9717-9738. 3. Zhang Y, et al. *Cancer Lett.* 2016;375(1):179-189.

**The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.**





Scan to learn more about the proposed mechanism of action of enfortumab vedotin

Clinical Trials<sup>a</sup>

			Phase 1	Phase 2	Phase 3
	RECRUITING	EV-302/KEYNOTE-A39 <sup>b</sup> : Untreated locally advanced or mUC (NCT04223856) Enfortumab vedotin + pembrolizumab vs chemotherapy			
	RECRUITING	KEYNOTE-905/EV-303 <sup>c</sup> : MIBC, ineligible for/decline cisplatin (NCT03924895) Perioperative pembrolizumab ± enfortumab vedotin + RC + PLND vs RC + PLND alone			
	RECRUITING	KEYNOTE-B15/EV-304 <sup>c</sup> : Cisplatin-eligible MIBC (NCT04700124) Perioperative enfortumab vedotin + pembrolizumab + RC + PLND vs neoadjuvant chemotherapy + RC + PLND			
	RECRUITING	EV-202: Locally advanced or metastatic malignant solid tumors (NCT04225117) Enfortumab vedotin alone			
	RECRUITING	EV-103/KEYNOTE-869 <sup>b,d</sup> : Urothelial cancer (NCT03288545) Enfortumab vedotin alone or with other therapies			
	RECRUITING	EV-104: Non-muscle invasive bladder cancer (NCT05014139) Intravesical enfortumab vedotin alone			

**MIBC:** muscle invasive bladder cancer; **mUC:** metastatic urothelial carcinoma; **RC + PLND:** radical cystectomy plus pelvic lymph node dissection

<sup>a</sup> Program being co-developed with Astellas Pharma Global Development, Inc.  
<sup>b</sup> Study sponsored by Astellas Pharma Global Development, Inc., in collaboration with Seagen Inc. and Merck Sharp & Dohme LLC.  
<sup>c</sup> Study sponsored by Merck Sharp & Dohme LLC, in collaboration with Seagen Inc. and Astellas Pharma Global Development, Inc.  
<sup>d</sup> Phase 1b/2.

Clinical trial information retrieved from clinicaltrials.gov, accessed October 2022.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc. Seagen and its logo are US registered trademarks of Seagen Inc. Other trademarks are property of their respective owners.